InSightec completes $30.9 million Series C financing round, led by GE Healthcare and other investors. Lands CE Marked approval for its ExAblate Neuro in the treatment of Parkinson's disease.
InSightec picked off $30.9 million in a Series C financing round, led by a $27.6 million investment from GE Healthcare and $3.3 million by other investors, the company said.
In addition, the Israeli-based ultrasound maker also named VP & general manager of the MRI business James Davis as new CEO and Tom Gentile as chairman of board. Gentile most recently was
president & CEO of GE Healthcare.
"With this additional investment GE and the other investors have renewed their longstanding commitment to the future of InSightec and focused ultrasound technology," Gentile said in prepared release. " InSightec continues to demonstrate its leadership and ability to deliver clinically proven, safe and effective therapy systems and creating non-invasive acoustical surgery centers used by multi-disciplinary groups of physicians for multiple clinical disorders."
InSightec will place Davis at the company's new U.S. commercial offices in Southeastern Wisconsin.
In a seperate release, InSightec's ExAblate Neuro in treatment of medication resistant Parkinson's disease received CE Marked approval in European Union.
The non-invasive transcranial focused ultrasound system ExAblate Neuro aims to destroy specific neural pathways associated with movement disorders in order to treat neurological disorders in the brain, including essential tremor, Parkinson's disease and neuropathic pain, according to the press release.
Teleflex expands a Class I recall for Maquet Servo 163 humidifiers and beats expectations with its...
Nikon, best known for its cameras, moves into medtech with Optos buy
A single human error in India prompts GE Healthcare to issue a warning on 30 years worth of its MRI...
Staar Surgical posts net losses for the 4th quarter and 2014 but comes close to meeting earnings...